Drugs /

furosemide

Back to Drugs List

Overview

NCI Definition [1]:
A sulfamoylanthranilic acid derivative, also known as frusemide, and potent loop diuretic. Furosemide is widely used to treat hypertension and edema. This agent is highly bound to albumin and is largely excreted unchanged in the urine.

Clinical Trials

View Clinical Trials for furosemide

Furosemide has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating furosemide, 1 is phase 1/phase 2 (1 open).

BCR-ABL1 Fusion, CBFB-MYH11 Fusion, and CEBPA Biallelic Mutation are the most frequent biomarker inclusion criteria for furosemide clinical trials.

Acute myeloid leukemia is the most common disease being investigated in furosemide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Furosemide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating furosemide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
furosemida, lasix (tn), fursemide, lb 502, 269420, furosemide (product), frs, frusemide, frusemid, furosemide, furosemide [chemical/ingredient], lb-502, lasix, furosemid, sk-furosemide, 54-31-9, furosemide, benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)-, furosemide (substance), furosemidu, furosemidum
NCIT ID [1]:
C515
SNOMED ID [1]:
C-72040

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.